Keywords
How to Cite
Abstract
Introduction. Neurotrophic keratitis (NK) is an orphan pathology caused by the damage of the trigeminal nerve with the subsequent degenerative changes of the corneal epithelium. Causes of NK include various genetic, systemic and infectious diseases, tumors of the central and peripheral nervous system, surgical interventions. Previously used methods of therapy were mostly symptomatic and did not allow to achieve complete restoration of corneal innervation and sensitivity. The use of topical cenegermin, a recombinant form of human nerve growth factor, in clinical practice allows significantly better control of NK in patients of all ages, regardless of the causative factor.
Case description. We present a clinical case of NK in an early age patient with a recurrent form of atypical teratoid rhabdoid tumor (ATRT) of the central nervous system (CNS) with complete resolution of NK due to cenegermin therapy.
Conclusion. Our experience demonstrates the efficiency, safety and feasibility of the method in an outpatient setting.
References
Dua H.S., Said D.G., Messmer E.M., et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018; 66: 107-131.-DOI: https://doi.org/10.1016/j.preteyeres.2018.04.003.
Versura P., Giannaccare G., Pellegrini M., et al. Neurotrophic keratitis: current challenges and future prospects. Eye and Brain. 2018; 10: 37-45.-DOI: https://doi.org/10.2147/EB.S117261.
Bonzano C., Bonzano E., Cutolo C.A., et al. A case of neurotrophic keratopathy concomitant to brain metastasis. Cureus. 10(3): e2309.-DOI: https://doi.org/10.7759/cureus.2309.
Aloe L., Rocco M.L., Balzamino B.O., et al. Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol. 2015; 13(3): 294-303.-DOI: https://doi.org/10.2174/1570159x13666150403231920.
Babayan-Sosa A., Baca-Loada O. Corneal epitheliopathy due to sensitive impairment: neutrophic keratitis. Rev Mex Oftamol. 2018; 92.-DOI: https://doi.org/10.24875/RMOE.M18000017.
Pedrotti E., Bonetto J., Cozzini T., et al. Cenegermin in pediatric neurotrophic keratopathy. Cornea. 2019; 38: 1450-2.-DOI: https://doi.org/10.1097/ICO.0000000000002112.
Kalhorn A.J., Tawse K.L., Shah A.A., et al. Maternal serum eye drops in the management of pediatric persistent corneal epithelial defects: a case series. Cornea. 2018; 37(7): 912-915.-DOI: https://doi.org/10.1097/ICO.0000000000001512.
Pedrotti E., Bonetto J., Cozzini T., et al. Cenegermin in pediatric neurotrophic keratopathy. Cornea. 2019; 38: 1450-2.-DOI: https://doi.org/10.1097/ICO.0000000000002112.
Bonini S., Lambiase A., Rama P., et al. Phase II randomized, double- masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018; 125(9): 1332-1343.-DOI: https://doi.org/10.1016/j.ophtha.2018.02.022.
Annex I. Summary of Product Characteristics. Oxervate 20. Committee for Medicinal Products for Human Use (CHMP). 2022; 27. URL: https://www.ema.europa.eu/en/documents/product-information/oxervate-epar-product-information_en.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761094s000lbl.pdf.
Bonini S., Lambiase A., Rama P., et al. REPARO Study Group. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018; 125(9): 1332-1343.-DOI: https://doi.org/10.1016/j.ophta.2018.02.022.
Pflugfelder S.C., Massaro-Giordano M., Perez V.L., et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020; 127(1): 14-26.-DOI: https://doi.org/10.1016/j.ophtha.2019.08.020.
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03836859, Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers; 26 Dec 2023. URL: https://clinicaltrials.gov/study/NCT03836859.
Australian public assessment report for cenegermin. The Therapeutic Goods Administration (TGA). The Australian Government Department of Health. 2019; 24. URL: https://www.tga.gov.au/sites/default/files/auspar-cenegermin-rbe-191126.docx.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024